Soligenix Inc. has reached a critical milestone in its clinical development program, completing enrollment of the 50 patients required for interim analysis in the confirmatory Phase 3 FLASH2 study evaluating HyBryte for cutaneous T-cell lymphoma. The interim analysis is scheduled for the second quarter of 2026, with topline data expected in the second half of that year.
The company reported an overall blinded response rate of 48 percent among patients who have completed treatment to date, substantially exceeding the anticipated 25 percent rate used in the study's powering assumptions. This higher response rate suggests stronger than expected efficacy for the novel photodynamic therapy. Investigators have noted safety findings consistent with earlier studies, with HyBryte continuing to demonstrate encouraging efficacy signals across the ongoing development program.
This advancement is particularly significant for patients with cutaneous T-cell lymphoma, a rare cancer with limited treatment options. The successful completion of this second Phase 3 study will support regulatory approvals sought for potential commercialization worldwide. The full press release detailing these developments is available at https://ibn.fm/zuCdx.
HyBryte represents a novel approach to treating CTCL as a photodynamic therapy utilizing safe visible light. The treatment's mechanism involves synthetic hypericin sodium, which is activated by visible light to target cancerous cells while minimizing damage to healthy tissue. This targeted approach could offer patients a more favorable safety profile compared to existing treatments.
The FLASH2 study's progress comes at a time when rare disease treatments face significant development challenges due to small patient populations and limited research funding. Soligenix's achievement in completing enrollment for this interim analysis demonstrates the company's commitment to addressing unmet medical needs in the rare disease space. Additional information about Soligenix and its development programs can be found in the company's newsroom at https://ibn.fm/SNGX.
Beyond the HyBryte program, Soligenix maintains a diversified pipeline including expansion of synthetic hypericin into psoriasis treatment, development of dusquetide for inflammatory diseases including oral mucositis in head and neck cancer, and vaccine programs targeting ricin toxin, filoviruses, and COVID-19. The company's public health solutions segment has been supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The completion of enrollment for this interim analysis represents a meaningful step forward in the development of new treatment options for patients with limited alternatives. As the study progresses toward its 2026 analysis timeline, the medical community will be watching closely for results that could potentially transform the treatment landscape for cutaneous T-cell lymphoma patients worldwide.
